arrow
S

Sophie Postel-Vinay

institut gustave roussy
H指数:48
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Paediatric therapeutic development workshop on desmoplastic small round cell tumours

儿科治疗药物开发研讨会关于纤维性小圆细胞肿瘤

2026-10-140
OAAI
Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer

西拉帕替尼(一种ATR激酶抑制剂)联合奥拉帕尼的安全性与有效性:在晚期实体瘤中的剂量递增研究及在晚期乳腺癌中的剂量扩展研究

2026-09-300
OAAI
Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial

Werner解旋酶抑制剂用于高级别微卫星不稳定性实体瘤:一项1期临床试验

2026-09-290
OA
Development and external validation of a prognostic score associated with poor outcomes in patients receiving immune checkpoint blockade-containing therapies enrolled in early-phase clinical trials

基于早期临床试验中接受免疫检查点阻断治疗患者的预后评分的开发与外部验证:与不良结局相关的评分

2026-07-010
PRE
Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study

早期肿瘤学临床试验纳入患者中的急性肾损伤,AKITEP研究的结果

2026-05-260
PRE
Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC

I期研究:评估ceralasertib(一种ATR激酶抑制剂)联合durvalumab治疗复发或转移性NSCLC或HNSCC患者的疗效。

2026-03-310
OAAI
Multi-omics profiling identified two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristics

多组学分析鉴定出两种具有不同信号通路和免疫特征的上皮样肉瘤分子亚型

2025-11-280
OAAI
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration5

MTAP缺失的实体瘤患者中MTA合作PRMT5抑制剂AMG 193的首次人体研究: I期剂量探索的结果5

2024-12-014
PRE
DETECTION OF CIRCULATING TUMOR DNA (CTDNA) IN CEREBROSPINAL FLUID (CSF) IN PATIENTS WITH GLIOBLASTOMA TREATED IN PHASE I CLINICAL TRIAL
2024-11-110
PRE
Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs
2024-06-012
OAAI
Efficacy and safety of ceralasertib in the PLANETTE study in patients (pts) with ATM-altered advanced solid tumors (ASTs) or metastatic castration-resistant prostate cancer (mCRPC)
2024-04-050
PRE
Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in desmoplastic small round cell tumors
2024-03-220
PRE
Clinical and translational results of the academic ARIANES Phase 2 basket study: Longitudinal single-cell analysis of patient tumors identifies biological correlates of response to PARP inhibitors and anti-PD-L1 therapy
2024-03-220
PRE
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA

胆道癌的分子谱分析揭示了循环和组织肿瘤DNA之间不同的基因组景观

2024-01-084
OA
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial
2023-12-142
PRE
Factors associated with primary resistance to immune checkpoint blockade in early phase clinical trials
2023-12-010
PRE